Your browser doesn't support javascript.
loading
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.
Shi, Sally Yu; Lu, Ya-Wen; Liu, Zhi; Stevens, Jennitte; Murawsky, Christopher M; Wilson, Vicki; Hu, Zhonghua; Richards, William G; Michaels, Mark Leo; Zhang, Jun; Yan, Wei; Li, Yang.
Afiliação
  • Shi SY; From Amgen Inc., South San Francisco, California 94080.
  • Lu YW; From Amgen Inc., South San Francisco, California 94080.
  • Liu Z; Amgen Inc., Thousand Oaks, California 91320, and.
  • Stevens J; Amgen Inc., Thousand Oaks, California 91320, and.
  • Murawsky CM; Amgen British Columbia Inc., Burnaby, British Columbia V5A 1V7, Canada.
  • Wilson V; Amgen British Columbia Inc., Burnaby, British Columbia V5A 1V7, Canada.
  • Hu Z; Amgen Inc., Thousand Oaks, California 91320, and.
  • Richards WG; From Amgen Inc., South San Francisco, California 94080.
  • Michaels ML; Amgen Inc., Thousand Oaks, California 91320, and.
  • Zhang J; From Amgen Inc., South San Francisco, California 94080.
  • Yan W; Amgen Inc., Thousand Oaks, California 91320, and.
  • Li Y; From Amgen Inc., South San Francisco, California 94080, yangln3101@gmail.com.
J Biol Chem ; 293(16): 5909-5919, 2018 04 20.
Article em En | MEDLINE | ID: mdl-29483191
ABSTRACT
Bispecific antibodies have become important formats for therapeutic discovery. They allow for potential synergy by simultaneously engaging two separate targets and enable new functions that are not possible to achieve by using a combination of two monospecific antibodies. Antagonistic antibodies dominate drug discovery today, but only a limited number of agonistic antibodies (i.e. those that activate receptor signaling) have been described. For receptors formed by two components, engaging both of these components simultaneously may be required for agonistic signaling. As such, bispecific antibodies may be particularly useful in activating multicomponent receptor complexes. Here, we describe a biparatopic (i.e. targeting two different epitopes on the same target) format that can activate the endocrine fibroblast growth factor (FGF) 21 receptor (FGFR) complex containing ß-Klotho and FGFR1c. This format was constructed by grafting two different antigen-specific VH domains onto the VH and VL positions of an IgG, yielding a tetravalent binder with two potential geometries, a close and a distant, between the two paratopes. Our results revealed that the biparatopic molecule provides activities that are not observed with each paratope alone. Our approach could help address the challenges with heterogeneity inherent in other bispecific formats and could provide the means to adjust intramolecular distances of the antibody domains to drive optimal activity in a bispecific format. In conclusion, this format is versatile, is easy to construct and produce, and opens a new avenue for agonistic antibody discovery and development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Receptor Tipo 1 de Fator de Crescimento de Fibroblastos / Fatores de Crescimento de Fibroblastos / Proteínas de Membrana Limite: Animals / Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Receptor Tipo 1 de Fator de Crescimento de Fibroblastos / Fatores de Crescimento de Fibroblastos / Proteínas de Membrana Limite: Animals / Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2018 Tipo de documento: Article